Keyphrases
Alzheimer's Disease
100%
Positron Emission Tomography
100%
Amyloid Plaques
100%
Interim Analysis
100%
Prodromal
100%
Gantenerumab
100%
Scarlet
66%
Open-label Extension
33%
Centiloids
33%
Florbetapir Positron Emission Tomography
33%
Receptor-mediated
16%
High Dose
16%
Clinical Efficacy
16%
Fc Receptor
16%
Monoclonal Antibody
16%
Trial Registration
16%
Standardized Uptake Value
16%
First Year
16%
Phase II Trial
16%
Titration
16%
Phagocytosis
16%
Clinical Diagnosis
16%
Clinical Benefit
16%
Amyloid Positivity
16%
Lines of Evidence
16%
Plaque Burden
16%
Ratio Method
16%
Visual Read
16%
Placebo-controlled Study
16%
Centiloid Scale
16%
Plaque Removal
16%
Florbetapir
16%
Medicine and Dentistry
Positron Emission Tomography
100%
Alzheimer's Disease
100%
Amyloid Plaque
100%
Interim Analysis
100%
Gantenerumab
100%
Amyloid Protein
83%
Drug Megadose
16%
Low Drug Dose
16%
Standardized Uptake Value
16%
Titrimetry
16%
Fc Receptor
16%
Phagocytosis
16%
Placebo-Controlled Study
16%
Human Monoclonal Antibody
16%
Plaque Removal
16%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
100%
Amyloid Plaque
100%
Gantenerumab
100%
Amyloid Protein
83%
Fc Receptor
16%
Placebo-Controlled Study
16%
Human Monoclonal Antibody
16%